Related Experiment Video
Updated: Aug 16, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Therapy of hormone refractory prostate cancer: new standards, new trends]
C Wülfing1, S Bierer, M Bögemann
1Klinik und Poliklinik für Urologie, Universitätsklinikum Münster. wulfing@uni-muenster.de
Abstract:
Hormone-refractory prostate cancer is diagnosed with increasing incidence and has become a growing challenge for urologists. The improved understanding of the tumor biological mechanisms of the hormone-refractory state has led to innovative therapeutic developments in the field of hormonal and cytotoxic therapies. Recently, two large randomized Phase III trials with docetaxel-based chemotherapy were able to show prolonged survival and a positive influence on pain and quality of life, establishing a new standard of care for these patients. Moreover, bisphosphonates seem to have positive influence on selected patients. In the growing field of molecular targeted therapy, first trials with compounds, such as tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors and endothelin receptor antagonists, show promising results in the treatment of patients with hormone-refractory prostate cancer.
Insights
Hormone-refractory prostate cancer treatment is advancing with docetaxel chemotherapy improving survival and quality of life. Emerging targeted therapies also show promise for this challenging condition.
Area of Science:
- Oncology
- Urology
Background:
- Hormone-refractory prostate cancer (HRPC) incidence is rising, posing a significant clinical challenge.
- Understanding HRPC's biology drives new therapeutic strategies.
Purpose of the Study:
- To review recent advancements in hormonal and cytotoxic therapies for HRPC.
- To highlight the potential of novel molecular targeted therapies.
Main Methods:
- Review of recent Phase III clinical trials, particularly those involving docetaxel-based chemotherapy.
- Assessment of emerging therapeutic compounds including tyrosine kinase inhibitors, anti-sense oligonucleotides, and angiogenesis inhibitors.
Main Results:
- Docetaxel-based chemotherapy demonstrated prolonged survival and improved quality of life in HRPC patients, establishing a new standard of care.
- Bisphosphonates showed positive effects in select HRPC patients.
- Early trials of molecular targeted therapies yielded promising outcomes.
Conclusions:
- Docetaxel chemotherapy represents a significant advancement in HRPC management.
- Molecular targeted therapies offer a promising future direction for HRPC treatment.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...